Biocept Inc.’s (BIOC) molecular diagnostic assays help physicians in treating and monitoring patients with different cancers. During the COVID-19 pandemic, Biocept has also used its molecular diagnostic expertise to provide nationwide COVID-19 RT-PCR testing. Let's take a look at the company's recent Q2 performance, as well as what has changed in its key risk factors that investors should be aware of. (See Biocept stock charts on TipRanks) Driven by RT-PCR testing volumes, Biocept’s Q2 revenue jumped 1,209% year-over-year to $12 million, but fell short of consensus by $5.71 million. Since June 2020, it has received about 500,000 samples for RT-PCR testing.
https://www.tipranks.com/news/gauging-biocepts-risk-factors-post-q2?utm_source=advfn.com&utm_medium=referral
Biocept (NASDAQ:BIOC)
Gráfico Histórico do Ativo
De Ago 2022 até Set 2022 Click aqui para mais gráficos Biocept.
Biocept (NASDAQ:BIOC)
Gráfico Histórico do Ativo
De Set 2021 até Set 2022 Click aqui para mais gráficos Biocept.